ResMed Earnings Call Transcripts
Fiscal Year 2026
-
Q2 FY2026 saw 11% revenue growth and 16% EPS growth, with strong performance in devices and masks, margin expansion, and robust cash flow. Continued investments in R&D, SG&A, and capital returns underpin confidence in sustained growth.
-
Strong revenue growth, margin expansion, and global reach are supported by innovation in AI-enabled devices, digital health, and strategic acquisitions. Big Tech and GLP-1 trends are driving patient flow, while U.S. manufacturing expansion and regulatory wins strengthen market position.
-
Q1 FY26 saw 9% revenue growth, 280 bps gross margin expansion, and double-digit EPS growth, driven by strong device and mask sales, SaaS focus, and innovation. Over $238M was returned to shareholders, with continued investment in R&D and U.S. manufacturing.
Fiscal Year 2025
-
The meeting approved all board proposals, including director elections, auditor ratification, executive compensation, and amendments to incentive and stock purchase plans. Strategic updates focused on AI-driven products, robust financial growth, and ongoing capital returns to shareholders.
-
ResMed outlined its 2030 strategy to improve 500 million lives, leveraging cloud-connected devices, data-driven research, and global expansion. Strong financials, product innovation, and targeted acquisitions support growth, while new reimbursement models and demand from GLP-1s and wearables drive patient engagement and adherence.
-
Q4 FY25 saw 10% revenue growth, 230 bps gross margin expansion, and strong cash flow, with robust global demand and continued investment in innovation and digital health. FY26 guidance includes higher margins, increased dividends, and share buybacks, supported by a solid balance sheet.
-
Q3 FY2025 saw strong revenue and margin growth, driven by manufacturing efficiencies, new product launches, and robust demand across regions. Tariff exemptions and a solid balance sheet support increased share buybacks and ongoing R&D investment.
-
Q2 FY25 saw 10% revenue growth, 230 bps gross margin expansion, and 29% EPS increase, driven by strong device and mask sales, digital health, and innovation. Guidance remains robust, with continued investment in R&D, share buybacks, and readiness for increased patient flow from GLP-1 and consumer tech trends.
-
A market leader in sleep and respiratory health, the company leverages digital health, AI, and software integration to drive innovation and patient adherence. GLP-1s are seen as a complementary tailwind, not a threat, with real-world data supporting increased therapy initiation and adherence. Financials remain strong, with high margins and ambitious growth targets.
-
Delivered 11% revenue growth and 27% higher operating profit, driven by strong device and mask sales, margin expansion, and digital health innovation. Guidance remains positive, with continued investment in R&D, tuck-in M&A, and share buybacks.
Fiscal Year 2024
-
Strong Q1 results and robust cash flow support increased dividends, buybacks, and ongoing innovation. GLP-1 drugs and consumer tech are expected to drive patient growth, with scalable digital and remote solutions in place. New mask technology and resupply initiatives aim to boost adherence and outcomes.
-
A new 2030 strategy targets accelerated growth through patient-centric innovation, digital health, and expansion into adjacencies like insomnia and COPD. Financial guidance calls for high single-digit revenue growth, margin expansion, and increased investment in R&D, digital tools, and global omni-channel marketing.
-
Global sleep apnea treatment remains underpenetrated, with strong growth potential in emerging markets and ongoing share gains following a competitor recall. Technology innovation, new product launches, and digital engagement are driving higher margins and adherence. Pharma and tech trends are expected to accelerate patient flow and market expansion.
-
Q4 FY24 delivered strong double-digit growth in revenue, net income, and EPS, driven by robust demand for devices, masks, and digital health solutions. Gross margin expanded to 59.1%, with FY25 guidance of 59%-60% despite freight headwinds.